Wolverine Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wolverine Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-126	Closed	-$14K	–	2319
2021 Q1	$14K	Buy	+126	New	+$14.7K	﹤0.01%	1812
2014 Q3	–	Sell	-203	Closed	-$28K	–	2582
2014 Q2	$28K	Sell	203 -214	-51%	-$31.3K	﹤0.01%	1599
2014 Q1	$62K	Sell	417 -888	-68%	-$175K	﹤0.01%	1274
2013 Q4	$239K	Buy	+1,305	New	+$239K	﹤0.01%	1080
2013 Q3	–	Sell	-217	Closed	-$37K	–	2796
2013 Q2	$37K	Buy	+217	New	+$56.6K	﹤0.01%	1798

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Wolverine Asset Management's MDGL Position: Q2 2021 in Review

Wolverine Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2021, closing a stake of 126 shares — an estimated $14K sold.

Wolverine Asset Management first reported a position in MDGL in Q2 2013 and held it in 5 quarters. The position peaked at $239K in Q4 2013. 151 funds tracked by Wall St. Rank hold MDGL as of Q2 2021.

Wolverine Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Wolverine Asset Management sold 126 Madrigal Pharmaceuticals shares in Q2 2021, an estimated $14K.
Wolverine Asset Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Wolverine Asset Management's Madrigal Pharmaceuticals position peaked at $239K in Q4 2013.
151 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2021.

Based on Wolverine Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.